Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 242

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Cost Effectiveness of Alternative Surveillance Strategies for Hepatocellular Carcinoma in Patients With Cirrhosis

Open access
Andersson, Karin L., Salomon, Joshua A., Goldie, Sue J., Chung, Raymond T.·2008·Clinical Gastroenterology and Hepatology

Abstract

Background & Aims The rising incidence of hepatocellular carcinoma (HCC) in the United States has significant health and economic consequences. Ultrasound (US) surveillance is recommended for patients with cirrhosis because of their high risk of HCC and improving treatment outcomes for small tumors. We assessed the costs, clinical benefits, and cost-effectiveness of US surveillance and alternative strategies for HCC in cirrhosis using a computer-based state transition model with parameters derived from available literature. Methods Our model compared a policy of no surveillance to six surveillance strategies in cirrhotic patients ages 50 years and older in the United States: 1) annual US; 2) semiannual US; 3) semiannual US with alphafetoprotein; 4) annual computed tomography (CT); 5) semiannual CT; and 6) annual magnetic resonance imaging. The number of screening tests needed to detect one small HCC, cost per treated HCC, lifetime costs, quality-adjusted life expectancy, and incremental cost-effectiveness ratios were calculated. Results Semiannual US surveillance for HCC in cirrhosis increased quality-adjusted life expectancy by 8.6 months on average, but extended it nearly 3.5 years in patients with small treated tumors. Semiannual US surveillance had an incremental cost-effectiveness ratio of $30,700 per quality-adjusted life year (QALY) gained, and was more cost-effective than the alternative surveillance strategies using a threshold of $50,000 per QALY gained. The incremental cost-effectiveness ratios for the combined alphafetoprotein/US and annual CT strategies exceeded $50,000/QALY unless the sensitivity and specificity of US fell below 65% and 60%, respectively. Conclusion Semiannual US surveillance for HCC in cirrhotic patients improves clinical outcomes at a reasonable cost.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2008.08.005

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 242

Metadata

Authors
Andersson, K. L., Salomon, J. A., Goldie, S. J., & Chung, R. T.
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2008-12
Volume
6
Issue
12
Pages
1418-1424
ISSN
1542-3565 (ISSN-L)
OpenAlex
W2076007540
Cited by
242
References
1
FWCI
4.23
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost Effectiveness of Alternative Surveillance Strategies for Hepatocellular Carcinoma in Patients With Cirrhosis. https://app.cochat.ai/papers/10.1016/j.cgh.2008.08.005
The paper
Andersson, K. L., Salomon, J. A., Goldie, S. J., & Chung, R. T. (2008). Cost Effectiveness of Alternative Surveillance Strategies for Hepatocellular Carcinoma in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2008.08.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.